Merrimack Pharmaceuticals Inc (MACK) May Be Right For Your Portfolio

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) may be the perfect biotech company for your speculative portfolio. The company had its Initial Public Offering in March of 2012 and raised $100 million for its operations. The sale of the public offering was at $7 dollars a share, valuing the company at $647 million. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) seems to have come to market at the right time, as it currently has eight drugs in it’s portfolio to bring long term value for investors. The price of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has been stagnant since its initial public offering as investors await for results from its late stage cancer trials.

Partnership

Biotech stocks that are at an early stage have a lot of trouble with raising capital and obtaining funding for trials. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is in a good spot as it already has two partnerships for it’s drug portfolio. MM-121 is one of these compounds–it is a monoclonal antibody that targets the ERbB3 cell surface receptor, and is partnered with Sanofi SA (ADR) (NYSE:SNY) for multiple cancer indications like ovarian cancer, breast cancer, and NSCLC cancer. MM-398 is the lead candidate for Merrimack as it is in a phase three trial for metastatic pancreatic cancer for patients who had previously failed treatment with Gemcitabine. It is partnered with Pharmengine, who hold rights in Taiwan for the drug. The best part about Merrimack’s MM-398 is that the FDA has granted it an orphan drug designation.

Pancreatic Cancer Market

To this day pancreatic cancer is one of the hardest forms of cancer to treat. The five year survival rate for people living with the disease is around 4% and the current therapies are toxic. The current therapies for pancreatic cancer aren’t extending the life of patients for long and more drugs are needed for this indication. If Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is successful in their phase three trial for MM-398 the company would have a huge market opportunity, as the pancreatic cancer market is set to be worth about $1.2 billion dollars by the year 2015.

Competitors

Merrimack faces some competition in the pancreatic cancer space. Two competing companies are Celgene Corporation (NASDAQ:CELG) and Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). Celgene announced in January of 2013 that patients who took the company’s drug Abraxane with Gemcitabine lived for 8.5 months longer, compared to those who took Gemcitabine alone and survived only 6.7 months. That’s a life extension of 1.8 months of patients who took Abraxane, which is better than standard care alone. Threshold has a drug that is currently in a phase 3 trial for pancreatic cancer, but in it’s phase 2 trial it reported a better life extension than Celgene’s Abraxane. Threshold reported a life extension of 9.2 months for patients treated with TH-302 compared to Gemcitabine alone at 6.7 months. Obviously Merrimack will have some competition in this space, but the company’s success or failure all depends on what they finally report in their phase three result of MM-398.

Final Thoughts

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has an array of cancer drugs in its pipeline that could bring lots of value for long term investors. It has been able to provide an initial public offering to provide adequate funding for their late stage trials and other administrative expenses. The pancreatic cancer market will grow to $1.2 billion dollars in 2015 and that could bring a huge opportunity for long term investors in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). If all goes well with MM-398 then the company’s valuation will be reevaluated to be higher because of the market potential for the drug. Investors should be aware of the fact that pancreatic cancer is the hardest form of cancer to treat, so the chances that the results will be outstanding will be small, but patience is needed in this biotech name.

The article Merrimack May Be Right For Your Portfolio originally appeared on Fool.com and is written by Terry Chrisomalis.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!